Lack of Association between NADPH Quinone Oxidoreductase 1 (NQO1) Gene C609T Polymorphism and Lung Cancer: A Case-Control Study and a Meta-Analysis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Guo, Shujie ^a   Gao, Min ^b   Li, Xiaobo ^a   Li, Yuqiong ^a   Chu, Shaoli ^a   Zhu, Dingliang ^a   Niu, Wenquan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; THYMINE;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CHINA; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAN CHINESE; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); NADPH QUINONE OXIDOREDUCTASE 1 GENE; POPULATION BASED CASE CONTROL STUDY; POPULATION DISTRIBUTION; POPULATION GENETICS; PROBABILITY; PUBLICATION; SAMPLE SIZE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FLUORESCENCE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84868118401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047939     Document Type: Article

References (42)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ, (2002) Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2: 37.
2. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M, (2006) NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 979-987.
3. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH, (1995) Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5: 199-206.
4. Heller G, Zielinski CC, Zochbauer-Muller S, (2010) Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 29: 95-107.
5. Schlager JJ, Powis G, (1990) Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45: 403-409.
6. Joseph P, Jaiswal AK, (1994) NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci U S A 91: 8413-8417.
7. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF, Peters GJ, (1995) DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 72: 917-921.
8. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, et al. (1997) DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 76: 923-929.
9. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, et al. (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res 52: 4752-4757.
10. Misra V, Grondin A, Klamut HJ, Rauth AM, (2000) Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer 83: 998-1002.
11. Siegel D, McGuinness SM, Winski SL, Ross D, (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9: 113-121.
12. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM, (1995) Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72: 555-561.
13. Guo S, Li X, Gao M, Kong H, Li Y, et al. (2012) Synergistic Association of PTGS2 and CYP2E1 Genetic Polymorphisms with Lung Cancer Risk in Northeastern Chinese. PLoS One 7: e39814.
14. Niu W, Zhang Y, Ji K, Gu M, Gao P, et al. (2010) Confirmation of top polymorphisms in hypertension genome wide association study among Han Chinese. Clin Chim Acta 411: 1491-1495.
15. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W264.
16. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
18. Duval S, Tweedie R, (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463.
19. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L, (1999) Association of the NAD(P)H:quinone oxidoreductase 609C->T polymorphism with a decreased lung cancer risk. Cancer Res 59: 3045-3048.
20. Lin Y, Lu X, Shao M, Liang Y, Li Y, (2000) NAD(P)H: quinone oxidoredictase gene polymorphism and susceptibility of lung cancer. J Thorac Oncol 6: 1826-1832.
21. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, et al. (2001) Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 33: 133-141.
22. Sunaga N, Kohno T, Yanagitani N, Sugimura H, Kunitoh H, et al. (2002) Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 11: 730-738.
23. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, et al. (2002) NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7: 103-108.
24. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, et al. (2003) Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 40: 123-129.
25. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, et al. (2004) Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25: 2177-2181.
26. Liang GY, Pu YP, Yin LH, (2004) Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. Yi Chuan 26: 584-588.
27. Chan EC, Lam SY, Fu KH, Kwong YL, (2005) Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 162: 10-20.
28. Yang M, Choi Y, Hwangbo B, Lee JS, (2007) Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer 57: 135-142.
29. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, et al. (2009) Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control 20: 137-145.
30. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC, (2001) Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 34: 177-183.
31. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, et al. (2001) The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 10: 303-309.
32. Alexandrie AK, Nyberg F, Warholm M, Rannug A, (2004) Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13: 908-914.
33. Bock CH, Wenzlaff AS, Cote ML, Land SJ, Schwartz AG, (2005) NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: results from a population-based study. Carcinogenesis 26: 381-386.
34. Lawson KA, Woodson K, Virtamo J, Albanes D, (2005) Association of the NAD(P)H:quinone oxidoreductase (NQO1) 609C->T polymorphism with lung cancer risk among male smokers. Cancer Epidemiol Biomarkers Prev 14: 2275-2276.
35. Saldivar SJ, Wang Y, Zhao H, Shao L, Lin J, et al. (2005) An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res 582: 71-78.
36. Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, et al. (2005) Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 48: 187-199.
37. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O, (2005) Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 221: 185-190.
38. Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer SK, et al. (2009) Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis 30: 626-635.
39. Timofeeva M, Kropp S, Sauter W, Beckmann L, Rosenberger A, et al. (2010) Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int J Cancer 127: 1547-1561.
40. Wiencke JK, Spitz MR, McMillan A, Kelsey KT, (1997) Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 6: 87-92.
41. Spector TD, Thompson SG, (1991) The potential and limitations of meta-analysis. J Epidemiol Community Health 45: 89-92.
42. Higgins JP, Thompson SG, Spiegelhalter DJ, (2009) A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 172: 137-159.